Two Sigma Securities’s BioXcel Therapeutics BTAI Stock Holding History

Two Sigma Securities’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,068	Closed	-$27.3K	–	1690
2025 Q4	$27.3K	Buy	+17,068	New	+$35.2K	﹤0.01%	1141
2025 Q1	–	Sell	-1,082	Closed	-$6.47K	–	1515
2024 Q4	$6.47K	Buy	+1,082	New	+$9.04K	﹤0.01%	1468

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Two Sigma Securities's BTAI Position: Q1 2026 in Review

Two Sigma Securities sold out of BioXcel Therapeutics (BTAI) in Q1 2026, closing a stake of 17,068 shares — an estimated $27.3K sold.

Two Sigma Securities first reported a position in BTAI in Q4 2024 and held it in 2 quarters. The position peaked at $27.3K in Q4 2025. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

Two Sigma Securities reported no remaining BioXcel Therapeutics position as of Q1 2026 after selling out during the quarter.
Two Sigma Securities sold 17,068 BioXcel Therapeutics shares in Q1 2026, an estimated $27.3K.
Two Sigma Securities first reported a position in BioXcel Therapeutics in Q4 2024 and held it in 2 quarters.
Two Sigma Securities's BioXcel Therapeutics position peaked at $27.3K in Q4 2025.
40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.